semaglutide and kidney problems in patients with overweight or obesity chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial semaglutide and chronic kidney disease

Internal Accolade document

Prioritizing protein intake and incorporating resistance training helps preserve muscle mass

Men using PT-141 off-label may report different efficacy patterns, though nausea remains a common adverse effect in both groups

What the research shows (& what it doesnt) Potential Benefits Many people lose a significant amount of weight (up to 15% of body weight in some trials) Appetite often decreases, sometimes dramatically Improvements in measures of blood glucose management, cholesterol, and blood pressure have been observed during clinical trials But here's whats also true: Known Risks and Gaps in Knowledge Short-term research : Most studies last no longer than 1-2 years